Immunotherapy Combined With Radiation and Influenza Vaccine for Pancreatic Cancer.
Status:
Not yet recruiting
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
Pancreatic cancer (PC) remains a dreadful disease due to its often advanced stage at
diagnosis and poor sensitivity to chemotherapy. Progression after 1. line chemotherapy is
inevitable in patients with advanced PC, and treatment options for patients who progress
after 1. line chemotherapy are limited. Considering the emerging role of the tumor
microenvironment, the combination of checkpoint blocking antibodies with immunomodulation of
the tumor microenvironment could lead to better responses in tumor historically resistant to
radiation and checkpoint blocking antibody approaches as single modalities. Influenza
vaccination in cancer patients receiving immune checkpoint inhibitors resulted in a better
survival, irrespective of the anticancer treatment outcome. Influenza vaccine facilitates
both T- and B cell activation and drives interferon-gamma response, supporting the rationale
for combining of influenza vaccine with immune checkpoint inhibition and radiation
(NCT02866383).
Based on these considerations, the proposed treatment with SBRT of 15 Gy in combination with
nivolumab, ipilimumab and influenza vaccine may have the potential to provide meaningful
clinical benefit by generating durable clinical responses, thereby improving quality of life
(QoL) and potentially extending survival.